Suchergebnisse - "Jones, Nicholas S"

PubPharm (32)

1

A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteers

enthalten in: Clinical and translational science | 2023

von Jones, N. | Kshirsagar, S. | Mohanan, V. | +11

2

Serious Infection Rates Among Patients with Select Autoimmune Conditions : A Claims-Based Retrospective Cohort Study from Taiwan and the USA

enthalten in: Rheumatology and therapy | 2023

von Huang, W. | Chuo, C. | Lin, C. | +6

3

Serious Infection Rates Among Patients with Select Autoimmune Conditions: A Claims-Based Retrospective Cohort Study from Taiwan and the USA

enthalten in: Rheumatology and therapy | 2022

von Huang, W. | Chuo, C. | Lin, C. | +6

4

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus : Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2021

von Isenberg, D. | Furie, R. | Jones, N. | +20

CommentIn: Arthritis Rheumatol. 2021 Oct;73(10):1773-1775. - PMID 34042321

5

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus : Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

enthalten in: Arthritis & Rheumatology | 2021

von Isenberg, D. | Furie, R. | Jones, N. | +20

6

Understanding the Effect of Hydroxypropyl-β-Cyclodextrin on Fenebrutinib Absorption in an Itraconazole-Fenebrutinib Drug-Drug Interaction Study

enthalten in: Clinical pharmacology and therapeutics | 2020

von Durk, M. | Jones, N. | Liu, J. | +8

7

Physiologically-Based Pharmacokinetic Model-Informed Drug Development for Fenebrutinib : Understanding Complex Drug-Drug Interactions

enthalten in: CPT: pharmacometrics & systems pharmacology | 2020

von Chen, Y. | Ma, F. | Jones, N. | +6

8

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI

enthalten in: Clinical pharmacology and therapeutics | 2020

von Jones, N. | Yoshida, K. | Salphati, L. | +3

9

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI

enthalten in: Clinical Pharmacology & Therapeutics | 2020

von Jones, N. | Yoshida, K. | Salphati, L. | +3

10

Pediatric Dose Selection and Utility of PBPK in Determining Dose

enthalten in: The AAPS journal | 2018

von Templeton, I. | Jones, N. | Musib, L.